Jazz Pharmaceuticals (BSP:J2AZ34) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:J2AZ34 Jazz Pharmaceuticals PLC BSP:J2AZ34
44 GF Score
Price R$87.12
GF Value R$51.81
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

BSP:J2AZ34
44GF Score
Jazz Pharmaceuticals PLC BSP:J2AZ34
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jazz Pharmaceuticals (BSP:J2AZ34) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of R$87.12 is trading 68.2% above its estimated GF Value™ of R$51.81. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BSP:J2AZ34:

  • FFO:
  • GF Value™: R$51.81 vs. price of R$87.12 (68.2% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the BSP:J2AZ34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
44GF Score

Get the complete analysis for BSP:J2AZ34

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$87.12
Price
R$51.81
GF Value